Dupixent® (dupilumab) late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at acaai

Dupixent significantly reduced itch and hive activity from baseline; 41% of patients achieved well-controlled disease status confirmatory data to support u.s. regulatory resubmission by year-end; if approved, dupixent would be the first new targeted treatment for people living with chronic spontaneous urticaria in more than 10 years more than 300,000 people in the u.s. suffer from chronic spontaneous urticaria that is inadequately controlled by antihistamines tarrytown, n.y. and paris, oct. 24, 2024 (globe newswire) -- regeneron pharmaceuticals, inc. (nasdaq: regn) and sanofi will present positive data from the phase 3 liberty-cupid study c evaluating the investigational use of dupixent® (dupilumab) in biologic-naÏve patients with uncontrolled chronic spontaneous urticaria (csu) who receive background therapy with antihistamines.
REGN Ratings Summary
REGN Quant Ranking